Antiretroviral treatment for HIV infection: Swedish recommendations 2016.
The Swedish Medical Products Agency and the Swedish Reference Group for Antiviral Therapy (RAV) have jointly published recommendations for the treatment of HIV infection on seven previous occasions (2002, 2003, 2005, 2007, 2009, 2011 and 2014). In February 2016, an expert group under the guidance of RAV once more revised the guidelines. The most important updates in the present guidelines are as follows: Tenofovir alafenamide (TAF) has recently been registered. TAF has several advantages over tenofovir disoproxilfumarate (TDF) and is recommended instead of TDF in most cases. First-line treatment for previously untreated individuals includes dolutegravir, boosted darunavir or efavirenz with either abacavir/lamivudine or tenofovir (TDF/TAF)/emtricitabine. Pre-exposure prophylaxis (PrEP) is recommended for high-risk individuals. As in the case of the previous publication, recommendations are evidence-graded in accordance with the Oxford Centre for Evidence Based Medicine ( http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/ ) ( Table 1 ). This document does not cover treatment of opportunistic infections and tumours. [Table: see text].
a Department of Clinical Pharmacology , Karolinska University Hospital and Division of Clinical Pharmacology and Department of Laboratory Medicine, Karolinska Institutet , Stockholm , Sweden.
Jaran
J
Eriksen
b Department of Microbiology, Tumor and Cell Biology , Karolinska Institutet and Department of Clinical Microbiology, Karolinska University Hospital , Stockholm , Sweden.
Jan
J
Albert
c Venhälsan, Södersjukhuset and The Swedish Agency for Public Health , Stockholm , Sweden.
Anders
A
Blaxhult
d Clinic of Infectious Diseases , Västmanland County Hospital , Västerås , Sweden.
Christina
C
Carlander
e Department of Infectious Diseases , Skåne University Hospital , Malmö , Sweden.
Leo
L
Flamholc
f Department of Infectious Diseases , Sahlgrenska Academy, University of Gothenburg , Sweden.
Magnus
M
Gisslén
g The Swedish Medical Products Agency , Uppsala , Sweden.
Filip
F
Josephson
h The Swedish Medical Products Agency, Uppsala and Department of Infectious Diseases , Karolinska University Hospital , Stockholm , Sweden.
Olof
O
Karlström
i Division of Pediatrics, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet and Department of Pediatrics , Karolinska University Hospital , Stockholm , Sweden.
Lars
L
Navér
j Department of Infectious Diseases , Karolinska University Hospital and Division of Infectious Diseases and Department of Medicine Huddinge, Karolinska Institutet , Stockholm , Sweden.
Veronica
V
Svedhem
k Department of Infectious Diseases , Sahlgrenska Academy, University of Gothenburg , Sweden.
Aylin
A
Yilmaz
l Division of Infectious Diseases, Department of Medicine Huddinge , Karolinska Institutet , Stockholm , Sweden ; All members of the Swedish Reference Group for Antiviral Therapy.
Anders
A
Sönnerborg
D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D000328:Adult; D000409:Alanine; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D015224:Dideoxynucleosides / Q000627:therapeutic use; D004338:Drug Combinations; D055088:Early Detection of Cancer; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006575:Heterocyclic Compounds, 3-Ring / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D008297:Male; D010078:Oxazines; D010879:Piperazines; D065129:Pre-Exposure Prophylaxis; D011728:Pyridones; D013548:Sweden; D000068698:Tenofovir / Q000031:analogs & derivatives; D000099226:Dolutegravir; D000099227:Abacavir
D000225:Adenine; D000409:Alanine; D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D004338:Drug Combinations; D006575:Heterocyclic Compounds, 3-Ring; D019259:Lamivudine; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D000068698:Tenofovir; D000099226:Dolutegravir; C492871:abacavir, lamivudine drug combination; D000099227:Abacavir; C442442:tenofovir alafenamide
Antiretroviral; HIV; Sweden; adult; paediatric; treatment guidelines